Laporan Kasus: Perbaikan Kadar Prolaktin pada Makroadenoma Hipofisis dengan Terapi Bromokriptin dan EETA
Abstract
Hiperprolaktinemia merupakan salah satu gejala klinis yang umum terjadi pada kasus makroadenoma hipofisis. Hiperprolaktinemia yang terjadi pada makroadenoma hipofisis dapat disebabkan oleh adanya penekanan massa tumor terhadap infundibulum (pituitary stalk) atau pun adanya sekresi hormon oleh tumor. Penelitian ini bertujuan untuk membahas pengaruh pemberian terapi bromokriptin dan operasi Endoscopic Endonasal Transsphenoidal Approach (EETA) terhadap perbaikan kadar hormon prolaktin dan kondisi klinis pada kasus makroadenoma hipofisis dengan hiperprolaktinemia. Dalam laporan kasus ini, dilaporkan bahwa seorang remaja pria usia 17 tahun datang dengan hilangnya penglihatan mata kanan, nyeri kepala, sulit menelan, dan ginekomasti. Pemeriksaan Magnetic Resonance Imaging (MRI) otak dengan kontras didapatkan adanya lesi ekstra aksial supratentorial di intrasellar yang meluas hingga suprasellar. Pada pemeriksaan laboratorium didapatkan adanya hiperprolaktinemia 198,10 ng/mL (nilai referensi 2,1–17,1 ng/mL). Hiperprolaktinemia yang terjadi pada kasus ini dapat disebabkan oleh tumor hipofisis yang mensekresi prolaktin (prolaktinoma) dan/atau akibat dari pendesakan massa tumor terhadap infundibulum. Berdasarkan hasil anamnesis, pemeriksaan fisik, pemeriksaan laboratorium dan penunjang, pasien didiagnosis mengalami makroadenoma hipofisis. Kami mempresentasikan kasus perbaikan kondisi klinis dan total penurunan kadar prolaktin sebesar 79,70% (pre pengobatan 198,10 ng/mL, post pengobatan 40,20 ng/mL) pada pasien dengan makroadenoma hipofisis yang disertai hiperprolaktinemia setelah dilakukan pemberian terapi bromokriptin 2,5 mg per hari selama 14 hari masa perawatan di rumah sakit dan tindakan operasi EETA.
Kata kunci: Bromokriptin, ginekomasti, hiperprolaktinemia, makroadenoma hipofisis
A Case Report: Prolactin Levels Improvement in Pituitary Macroadenoma with Bromocriptine Therapy and EETA
Abstract
Hyperprolactinemia is one of the common clinical symptoms of pituitary macroadenoma. Hyperprolactinemia that occurs in pituitary macroadenoma can be caused by the suppression of the tumor mass against the infundibulum (pituitary stalk) or due to hormone secretion by the tumor. This study aims to discuss the effect of bromocriptine therapy and Endoscopic Endonasal Transsphenoidal Approach (EETA) surgery on prolactin level and clinical conditions in pituitary macroadenoma with hyperprolactinemia. This case report presents a seventeen years old boy with loss of right eye vision, headache, swallowing difficulty, and gynecomastia. Brain Magnetic Resonance Imaging (MRI) scan with contrast media found an extra-axial supratentorial lesions extending to the suprasellar. Also, based on laboratory examination, hyperprolactinemia was found with prolactin level of 198.10 ng/mL (reference value 2.1–17.1 ng/mL). Hyperprolactinemia that occurred in this case was found to be caused by a prolactin-secreting pituitary tumor (prolactinoma) towards the infundibulum. Based on the anamnesis, physical examination, laboratory test, and MRI, the patient was diagnosed of pituitary macroadenoma. An improvement was also observed in clinical conditions, where prolactin levels decreased by 79.70% (pre and post treatment 198.10 ng/mL and 40.20 ng/mL, respectively) after 2.5 mg bromocriptine therapy administration for 14 days and EETA surgery therapy.
Keywords: Bromocriptine, gynecomastia, hyperprolactinemia, pituitary macroadenoma
Keywords
Full Text:
PDF (Bahasa Indonesia)References
Lake MG, Krook LS, Cruz SV. Pituitary adenomas: An overview. Am Fam Physician. 2013;88(5):31–27.
Molitch ME. Diagnosis and treatment of pituitary adenomas: A review. J Am Med Assoc. 2017;317(5):516–24. doi: 10.1001/jama.2016.19699
Hidayat M. Adenoma hipofisis. Maj Kedokt Andalas. 2015;38(2):130–8. doi: 10.22338/mka.v38.i2.p130-138.2015
Herse P. Pituitary macroadenoma: A case report and review. Clin Exp Optom. 2014;97(2):125–32. doi: 10.1111/cxo.12099
Zijlker H, Schagen S, Wit JM, Biermasz N, Furth W van, Oostdijk W. Pituitary adenoma apoplexy in an adolescent: A case report and review of the literature. J Clin Res İn Pediatr Endocrinol. 2017; 9(3):265–73. doi: 10.4274/jcrpe.4420
Guaraldi F, Storr HL, Ghizzoni L, Ghigo E, Savage MO. Paediatric pituitary adenomas: A decade of change. Horm Res Paediatr. 2014;81(3):145–55. doi: 10.1159/000357673
Chen J, Schmidt RE, Dahiya S. Pituitary adenoma in pediatric and adolescent populations. J Neuropathol Exp Neurol. 2019;78(7):626–32. doi: 10.1093/jnen/nlz040
Locatelli D, Veiceschi P, Castelnuovo P, Tanriover N, Evliyaoglu O. Transsphenoidal surgery for pituitary adenomas in pediatric patients: A multicentric retrospective study. Child’s Nerv Syst. 2019;35(11):2119–26. doi: 10.1007/s00381-019-04179-z
Majumdar A, Mangal NS. Hyperprolactinemia. J Hum Reprod Sci. 2013;6(3):168–75. doi: 10.4103/0974-1208.121400
Huang W, Molitch ME. Evaluation and management of galactorrhea. Am Fam Physician. 2012;85(11):1073–80.
Klein DA, Paradise SL, Reeder RM. Amenorrhea: A systematic approach to diagnosis and management. Am Fam Physician. 2019;100(1):39–48.
Iglesias P, Díez JJ. Macroprolactinoma: A diagnostic and therapeutic update. QJM An Int J Med. 2013;106(6):495–504. doi: 10.1093/qjmed/hcs240
Salenave S, Ancelle D, Bahougne T, Raverot G, Kamenicky P, Bouligand J, et al. Macroprolactinomas in children and adolescents: Factors associated with the response to treatment in 77 patients. J Clin Endocrinol Metab. 2015;100(3):1177–86. doi: 10.1210/jc.2014-3670
Tortosa F, Webb SM. Novel aspects in histopathology of the pituitary gland. Endocrinol Diabetes Nutr. 2017;64(3):152–61. doi: 10.1016/j.endinu.2016.10.004
López MÁC, Rodríguez JLR, García MR. Physiological and pathological hyperprolactinemia: Can we minimize errors in the clinical practice? In: Nagy GM, Toth BE, eds. Prolactin. InTech; 2013:213–30. doi: 10.5772/54758
Marino AC, Taylor DG, Desai B, Jr JAJ. Surgery for pediatric pituitary adenomas. Neurosurg Clin N Am. 2019;30(4):465–71. doi: 10.1016/j.nec.2019.05.008
Neto LV, Boguszewski CL, de Araújo LA, Bronstein MD, Miranda PAC, de C Musolino NR, et al. A review on the diagnosis and treatment of patients with clinically nonfunctioning pituitary adenoma by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. Arch Endocrinol Metab. 2016;60(4):374–90. doi: 10.1590/2359-3997000000179
Wong A, Anderson J, Couldwell WT, Liu JK. Update on prolactinomas. Part 2: Treatment and management strategies. J Clin Neurosci. 2015;22(10):1568–74. doi: 10.1016/j.jocn.2015.03.059
Ma Q, Su J, Li Y, Wang J, Long W, Luo M. The chance of permanent cure for micro- and macroprolactinomas, medication or surgery? A systematic review and meta-analysis. Front Endocrinol (Lausanne). 2018;9:636. doi: 10.3389/fendo.2018.00636
Oki Y. Medical management of functioning pituitary adenoma: An update. Neurol Med Chir (Tokyo). 2014;54(12):958–65. doi: 10.2176/nmc.ra.2014-0239
Bronstein MD. Endocrinology: Adult and pediatric. In: Jameson JL, De Groot LJ, de Kretser DM, Guidice LC, Grossman AB, Melmed S, et al. Endocrinology: Adult and pediatric. 7th ed. Philadelphia: Elsevier Saunders; 2016.
Cho KR, Jo K-I, Shin HJ. Bromocriptine therapy for the treatment of invasive prolactinoma: The single institute experience. Brain Tumor Res Treat. 2013;1(2):71–77. doi: 10.14791/btrt.2013.1.2.71
Araújo C, Marques O, Almeida R, Santos MJ. Macroprolactinomas: Longitudinal assessment of biochemical and imaging therapeutic responses. Endocrine. 2018; 62:470–76. doi: 10.1007/s12020-018-1703-4
Greenman Y, Cooper O, Yaish I, Robenshtok E, Sagiv N, Jonas-Kimchi T, et al. Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists. Eur J Endocrinol. 2016;175(1):63–72. doi: 10.1530/EJE-16-0206
Vilar L, Abucham J, Albuquerque JL, Araujo LA, Azevedo M, Boguszewski CL, et al. Controversial issues in the management of hyperprolactinemia and prolactinomas–An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. Arch Endocrinol Metab. 2018;62(2):236–63. doi: 10.20945/2359-3997000000032
DOI: https://doi.org/10.15416/ijcp.2020.9.3.237
Refbacks
- There are currently no refbacks.
Indonesian Journal of Clinical Pharmacy is indexed by